Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Oct 28;9(20):5190-5191.
doi: 10.1182/bloodadvances.2025017434.

Post-HCT gilteritinib outweighs conditioning in NPM1m FLT3-ITD AML

Aaron James Stonestrom  1 , Maria R Baer  1
Affiliations
Editorial

Post-HCT gilteritinib outweighs conditioning in NPM1m FLT3-ITD AML

Aaron James Stonestrom et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Comment on

  • Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia.
    Levis MJ, Hamadani M, Logan BR, Jones RJ, Singh AK, Litzow MR, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Oshima MU, Uy GL, Waller EK, Vasu S, Solh M, Mishra A, Muffly LS, Kim HJ, Stelljes M, Najima Y, Onozawa M, Thomson K, Chen C, Hasabou N, Rosales M, Hill JE, Gill SC, Nuthethi R, King D, Mendizabal A, Devine SM, Horowitz MM, Chen YB. Levis MJ, et al. Blood Adv. 2025 Oct 28;9(20):5123-5133. doi: 10.1182/bloodadvances.2025016306. Blood Adv. 2025. PMID: 40590852 Free PMC article. Clinical Trial.

References

    1. Levis M, Mehdi Hamadani M, Logan BR, et al. Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3 ITD acute myeloid leukemia. Blood Adv. 2025;9(20):5123–5133. - PMC - PubMed
    1. Levis MJ, Hamadani M, Logan B, et al. Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3. J Clin Oncol. 2024;42(15):1766–1775. - PMC - PubMed
    1. Levis MJ, Hamadani M, Logan BR, et al. Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML. Blood. 2025;145(19):2138–2148. - PMC - PubMed
    1. Reville PK, Sasaki K, Kantarjian HM, et al. Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: revisiting the European LeukemiaNet adverse risk classification. Am J Hematol. 2022;97(3):329–337. - PMC - PubMed
    1. Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454–464. - PMC - PubMed